Finerenone significantly decreased urinary albumin-to-creatinine ratio (MD -0.30; 95% CI -0.33 to -0.27) and reduced the risk of ≥40% eGFR decline (RR 0.85; 95% CI 0.78-0.93) compared to placebo.
Meta-Analysis (n=13,945)
Does finerenone improve renal function and reduce UACR in patients with diabetic kidney disease?
In patients with diabetic kidney disease, finerenone significantly reduces albuminuria and the risk of substantial eGFR decline, albeit with an increased risk of hyperkalemia.
Mean Difference: -0.3 (95% CI -0.33–-0.27)
p-value: p=< 0.05
Background: The phase III clinical trial of the nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) has been completed, aiming to investigate renal and cardiovascular outcomes in type 2 diabetes (T2D) with chronic kidney disease (CKD). However, the efficacy and safety of finerenone in renal function remain controversial. The purpose of this study was to explore the efficacy and safety of finerenone in treating the patients with diabetic kidney disease (DKD). Methods: Databases of PubMed, Cochrane Library, Embase, and Web of Science were searched for randomized controlled trials (RCTs) on patients with DKD receiving finerenone treatment from inception to September 2021. Data including patient characteristics and interested outcomes were extracted, and the dichotomous data and continuous variables were evaluated using risk ratio (RR) with 95% confidence intervals (CIs) and mean differences (MD) with 95% CIs, respectively. Results: A total of 4 RCTs involving 13,945 patients were included in this meta-analysis. Analysis results demonstrated that patients receiving finerenone showed a significant decrease in changing urinary albumin-to-creatinine ratio (UACR) from baseline (MD: −0.30; 95% CI −0.33, −0.27, p = 0.46, I2 = 0%) (p 0.05). The number of patients with ≥40% reduction in estimated glomerular filtration rate (eGFR) from baseline in the finerenone group was significantly smaller than that in the placebo group (RR: 0.85; 95% CI 0.78, 0.93, p = 0.60, I2 = 0%) (p 0.05). No difference was found in adverse events between the finerenone and placebo groups (RR: 1.00; 95% CI 0.98, 1.01, p = 0.94, I2 = 0%) (p = 0.65). The incidence of hyperkalemia was higher in the finerenone group than that in the placebo group (RR: 2.03; 95% CI 1.83, 2.26, p = 0.95, I2 = 0%) (p 0.05). Conclusion: Finerenone contributes to the reduction of UACR and can ameliorate the deterioration of renal function in patients with T2D and CKD. The higher risk of hyperkalemia was found in the finerenone group compared with placebo; however, there was no difference in the risk of overall adverse events.
Zheng et al. (Sat,) conducted a meta-analysis in Diabetic Kidney Disease (n=13,945). Finerenone vs. Placebo was evaluated on change in urinary albumin-to-creatinine ratio (UACR) from baseline (MD -0.30, 95% CI -0.33 to -0.27, p=< 0.05). Finerenone significantly decreased urinary albumin-to-creatinine ratio (MD -0.30; 95% CI -0.33 to -0.27) and reduced the risk of ≥40% eGFR decline (RR 0.85; 95% CI 0.78-0.93) compared to placebo.